NCT00652327View on ClinicalTrials.gov

Comparison of Ezetimibe Added to Ongoing Statin Therapy Versus Doubling the Dose of Statin in the Treatment of Hypercholesterolemia (P04355)

PHASE4CompletedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

July 31, 2007

Study Completion Date

July 31, 2007

Conditions
Hypercholesterolemia
Interventions
DRUG

Ezetimibe + Statin (simvastatin, atorvastatin, or pravastatin)

ezetimibe 10 mg plus ongoing statin (simvastatin 20 mg or atorvastatin 10 mg or pravastatin 20 mg) once daily for 8 weeks

DRUG

Double Statin (simvastatin, atorvastatin, or pravastatin)

simvastatin 40 mg or atorvastatin 20 mg or pravastatin 40 mg once daily for 8 weeks

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Organon and Co

INDUSTRY

NCT00652327 - Comparison of Ezetimibe Added to Ongoing Statin Therapy Versus Doubling the Dose of Statin in the Treatment of Hypercholesterolemia (P04355) | Biotech Hunter | Biotech Hunter